Bavarian Nordic is building a new fill-finish manufacturing line in Denmark to bring Imvamune manufacturing in-house.

PaxVax has two FDA-approved vaccines that could deliver about $70 million to $90 million to Emergent’s top line in 2019.

A blockchain-based drug and vaccine traceability system, which the developer says records all data in the vaccine supply chain, will debut in Shanghai.

Initial lab work suggests that the Ebola Zaire strain—the one targeted by Merck's rVSV-ZEBOV—is likely the cause of this outbreak.

GSK, Merck, Sanofi, Pfizer and Seqirus topped the world's biggest vaccine companies list by 2017 revenue.

Here is some other vaccine news of note for the week.

Merck's HPV shot, Gardasil, continued to gain steam in the second quarter, and execs see "significant" growth prospects ahead.

Sanofi will increase the supplies of Flublok Quadrivalent and Fluzone High-Dose to 25 million doses for the coming flu season.